This inventor holds 60 USPTO granted patents, primarily in Dihydropyridine Derivatives (CPC class 5143). Top assignees: Bayer Aktiengesellschaft, Triton Technology, Inc.. Active years: 1985-1998.
Inventors with similar research interests:
Company Filing History:
Years Active: 1985-1998
Areas of Expertise:
Title: Rainer Gross: Innovator in Cardiovascular Medicament Patents
Introduction
Rainer Gross is a prominent inventor based in Wuppertal, Germany, known for his significant contributions to the field of medicinal chemistry. With an impressive portfolio of 60 patents, Gross has specialized in the development of innovative compounds aimed at treating cardiovascular diseases.
Latest Patents
Among his latest innovations are the patents for 4-bicyclically substituted dihydropyridines and 3-quinolyl-substituted dihydropyridines. The former invention relates to new 4-bicyclically substituted dihydropyridines of a specified general formula, detailing processes for their preparation and applications in medicaments. These compounds are particularly valuable in the treatment of cardiovascular diseases. The latter invention focuses on 3-quinolyl-substituted dihydropyridine derivatives, which can also be utilized as pharmaceutically acceptable salts for treating cardiovascular conditions.
Career Highlights
Throughout his career, Rainer Gross has made significant strides in the pharmaceutical industry. He has worked with esteemed companies such as Bayer Aktiengesellschaft and Triton Technology, Inc. His work in these organizations has played a crucial role in advancing medicinal chemistry, especially in the realm of cardiovascular health.
Collaborations
Rainer Gross has collaborated with notable professionals in the field, including Martin Bechem and Matthias Schramm. These partnerships have fostered a collaborative environment that has strengthened the innovation of new medicinal compounds.
Conclusion
Rainer Gross continues to be a vital figure in the realm of pharmaceuticals, with a commendable number of patents under his name. The innovations stemming from his work not only showcase his expertise but also hold the potential to significantly impact the treatment of cardiovascular diseases, contributing to the overall advancement of medical science.